Enigma Diagnostics, a developer of next generation rapid molecular diagnostic instrument platforms for decentralized and point-of-care settings, has completed the European Commission Framework 7 programme.
In October 2007, the EU had awarded a EURO3m grant to Enigma Diagnostics to develop a rapid, fully automated molecular diagnostic system for Seasonal Influenza (circulating strains of Influenza types A & B) based on Enigma’s concept ML (mini-laboratory) instrument system.
The RANGER project started on 1 July 2008 was led by Enigma Diagnostics and included the UK Health Protection Agency (HPA) with responsibility for assay development, Sagentia (Harston, Cambridge, UK) supporting development of the Enigma ML prototype system and Queen Sirikit National Institute of Child Health collecting samples for clinical trials.
Enigma chairman John McKinley said the company and the entire RANGER consortium recognize the valuable contribution of the EU Commission in supporting the successful development of the Enigma ML system.
"This has progressed from initial design concept to pre-clinical assessment of the Seasonal Influenza test at the HPA Porton Down laboratories earlier this year. The Enigma ML system will now move to the commercialization stage during 2012.